NCAM1 and neoplasm: We subsequently demonstrated robust anti-tumour functions of CD3-CD56+ NK cells (S1 Fig) when challenged with each tumour cell line, quantified by CD107a expression on the NK cell surface and intracellular IFNγ production (Fig 1C and 1D).